Key Takeaways:
GeneDx Holdings Corp. faces a securities class action alleging executives misled investors about the Fabric Genomics acquisition, after the stock lost 49.2% of its value in a single day.
"The complaint challenges whether generic safe harbor warnings were sufficient given what executives allegedly already knew about Fabric's deteriorating viability," Joseph E. Levi, a partner at Levi & Korsinsky, said.
The class period runs from April 16, 2025 through May 4, 2026. On May 5, GeneDx disclosed a $31.2 million impairment charge tied to the Fabric Genomics acquisition and slashed full-year 2026 revenue guidance by approximately $65 million, from a prior range of $540 million to $555 million. Shares fell $33.42 to close at $34.52, erasing nearly half the company's market value in a single session.
The lawsuit, filed by Hagens Berman and supported by Levi & Korsinsky, alleges GeneDx made materially false statements about the acquisition's potential to generate recurring software revenue, reduce costs, and strengthen the company's competitive position. The complaint contends that integration challenges were undermining promised cost efficiencies, that the recurring software revenue model was failing to materialize, and that blended average reimbursement rates had fallen from over $3,800 to $3,300 in just two quarters. The lead plaintiff deadline is Aug. 3, 2026.
What the lawsuit alleges was missing from disclosures
The securities action asserts that GeneDx's public statements omitted specific material information necessary for investors to assess the Fabric acquisition's true state. According to the complaint, Fabric was proving suitable only for international markets rather than the broad domestic and global platform initially described, and the acquisition's goodwill and intangible assets were at risk of significant impairment.
The Private Securities Litigation Reform Act's safe harbor for forward-looking statements does not protect companies that make projections while allegedly concealing known problems, the complaint argues. Generic warnings that "acquisitions may not achieve expected results" cannot substitute for disclosing specific, known issues already affecting operations, according to the filing.
What happens next for investors
The Aug. 3 lead plaintiff deadline applies only to investors seeking to represent the class. Under the PSLRA, the court appoints the investor with the largest documented financial interest to direct the litigation. Class members who do not seek lead plaintiff status retain their rights to participate in any future settlement or judgment. Securities class actions are handled on a contingency basis, with no upfront costs to investors.
The 49% decline puts GeneDx shares at their lowest level since before the Fabric Genomics acquisition was announced. The next catalyst for the stock is the lead plaintiff appointment process, which typically takes several weeks after the Aug. 3 deadline, followed by the company's response to the complaint.
This article is for informational purposes only and does not constitute investment advice.
